Prot #CRSP-AID-500: A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

Project: Research project

Project Details

StatusActive
Effective start/end date4/17/25 → 5/16/28

Funding

  • Medpace Clinical Research LLC (Prot #CRSP-AID-500 // Prot #CRSP-AID-500)
  • CRISPR Therapeutics AG (Prot #CRSP-AID-500 // Prot #CRSP-AID-500)